Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States.


Journal Article

PURPOSE: This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting. METHODS AND MATERIALS: A nomogram-based survey was developed at the Seattle Prostate Institute defining the accepted criteria for intermediate-risk prostate cancer. Patients were defined as having intermediate-risk prostate cancer if they met one of the following criteria: prostate-specific antigen (PSA) >10 ng/dL, Gleason score (GS) > or = 7, or cT2b or cT2c disease. Additional potential predictive factors including perineural invasion (PNI), GS 3+4 vs. 4+3, and high-volume disease were included. RESULTS: In the absence of PNI, all of those surveyed would perform monotherapy for intermediate-risk patients, GS 7 (3+4) or PSA 10-20, with cT1c and <30% cores +. Up to 80% would perform monotherapy for patients with cT1c, GS 7 (4+3), and <30% cores +. Eighty to 90% of physicians would perform an implant alone with cT2a and either a PSA of 10-20 or GS of 7 (3+4) and <30% cores +. Fifty to 60% of those surveyed stated that they would treat a patient with cT2b disease, GS 7 (3+4), or PSA 11-20, with less than two-thirds of the biopsy cores positive in the absence of PNI. CONCLUSIONS: This Patterns of Care (POC) study reveals that certain subsets of intermediate-risk localized prostate cancer patients are considered appropriate candidates for an interstitial implant alone.

Full Text

Duke Authors

Cited Authors

  • Frank, SJ; Grimm, PD; Sylvester, JE; Merrick, GS; Davis, BJ; Zietman, A; Moran, BJ; Beyer, DC; Roach, M; Clarke, DH; Stock, RG; Robert Lee, W; Michalski, JM; Wallner, KE; Hurwitz, M; Potters, L; Kuban, DA; Prestidge, BR; Vera, R; Hathaway, S; Blasko, JC

Published Date

  • January 1, 2007

Published In

Volume / Issue

  • 6 / 1

Start / End Page

  • 2 - 8

PubMed ID

  • 17284379

Pubmed Central ID

  • 17284379

International Standard Serial Number (ISSN)

  • 1538-4721

Digital Object Identifier (DOI)

  • 10.1016/j.brachy.2006.09.004


  • eng

Conference Location

  • United States